HomeAI · summaries
Storia in 2 fonti
New data may cast doubt on competitiveness of Boehringer’s obesity drug
Boehringer Ingelheim’s obesity drug showed promise in cutting liver fat, but it was less impressive at overall weight loss, new data shows.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
Detailed data show Pfizer’s monthly obesity drug continues to show potential
Detailed data from a midstage study offered further evidence that the obesity drug Pfizer acquired from the biotech Metsera could be dosed monthly.
- ·
Lilly shares safety, tolerability data on its next-gen obesity drug
Eli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on Saturday.
